NEW YORK, June 1, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), announces the voting results of the Company's annual general and special meeting of shareholders held on June 1, 2022 (the "Meeting").
The five nominees of management were elected as directors at the Meeting. The voting results for the election of each director nominee are as follows:
At the Meeting, KPMG LLP was appointed as the auditor of the Company for the ensuing year and the directors were authorized to fix the remuneration to be paid to the auditor.
Alteration to the Company's Share Structure
At the Meeting, shareholders approved the alteration to the Company's share structure to eliminate the Multiple Voting Shares of the Company and re-designate the Subordinate Voting Shares as Common Shares of the Company.
MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
For Media: firstname.lastname@example.org
For Investors: email@example.com
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mindmed-announces-voting-results-for-annual-general-and-special-meeting-301559628.html
SOURCE Mind Medicine (MindMed) Inc.
Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2022/01/c8912.html
The work included in this article is based on current events, technical charts, company news releases, and the author’s opinions. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. This publication contains forward-looking statements, including but not limited to comments regarding predictions and projections. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. This publication is provided for informational and entertainment purposes only and is not a recommendation to buy or sell any security. Always thoroughly do your own due diligence and talk to a licensed investment adviser prior to making any investment decisions. Junior resource and biotechnology companies can easily lose 100% of their value so read company profiles on www.SEDAR.com for important risk disclosures. It’s your money and your responsibility.